Evaluation of the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-Labeled SRT2104 in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2011
At a glance
- Drugs SRT 2104; SRT 2104
- Indications Chronic obstructive pulmonary disease; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record